Drugs / SYSA1901
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05720026 | Jan 2023 → Aug 2025 | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYSA1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05720026 ↗ |
| Route | Intravenous | “SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously” NCT05720026 ↗ |